Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study

The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club

(2016) E. Cavalier et al.   OSTEOPOROSIS INTERNATIONAL

Bone Health and Osteoporosis

(2015) Beatrice C. Lupsa et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2015) Dennis M. Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Projection of osteoporosis-related fractures and costs in China: 2010–2050

(2015) L. Si et al.   OSTEOPOROSIS INTERNATIONAL

Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women

(2015) Susan L. Greenspan et al.   JAMA Internal Medicine

Risk of Atypical Femoral Fracture during and after Bisphosphonate Use

(2014) Jörg Schilcher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Calcium Supplementation: Is Protecting Against Osteoporosis Counter to Protecting against Cardiovascular Disease?

(2014) Connie M. Weaver   Current Osteoporosis Reports

RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk

(2013) Elizabeth J Samelson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis

(2013) E. Michael Lewiecki et al.   JOURNAL OF CLINICAL DENSITOMETRY

A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures

(2013) L. Si et al.   OSTEOPOROSIS INTERNATIONAL

Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

(2012) Michael McClung et al.   AMERICAN JOURNAL OF MEDICINE

Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial

(2012) Andrew Grey et al.   BONE

Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy

(2012) Cherie Ying Chiang et al.   BONE

Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management

(2012) Kurt A. Kennel et al.   MAYO CLINIC PROCEEDINGS

Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis

(2012) K. Ganda et al.   OSTEOPOROSIS INTERNATIONAL

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2012) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Rapidly increasing rates of hip fracture in Beijing, China

(2011) Wei-Bo Xia et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

(2011) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Spinal Trauma in Mainland China From 2001 to 2007

(2011) Peng Liu et al.   SPINE

Osteoporosis treatments and adverse events

(2009) Daniel H Solomon et al.   CURRENT OPINION IN RHEUMATOLOGY